Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pain 14Multiple Myeloma 12Pain, Postoperative 10Neoplasms 9Agnosia 8Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Cancer Pain 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Head and Neck Neoplasms 4Burkitt Lymphoma 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Trigger Finger Disorder 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Mantle-Cell 2

Interventions

Dexamethasone 12Bortezomib 9Lenalidomide 7Cyclophosphamide 5isatuximab 3fludarabine 3daratumumab 3Granulocyte Colony-Stimulating Factor 3pomalidomide 2filanesib 2dacetuzumab 2Tacrolimus 2Steroids 2Injections, Subcutaneous 2Filgrastim 2Clinical Protocols 2Calcium Dobesilate 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tissue Banks 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × Acetaminophen × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡